About: Blosozumab

Property	Value
dbo:abstract	بلوسوزوماب هو جسم مضاد وحيد النسيلة يدرب ليستخدم في علاج تخلخل العظم. طورته . (ar) Blosozumab binds SOST, a negative regulator of osteoblast activity. Blocking SOST activity can lead to increased bone density. Blosozaumab has been studied with regards to the treatment of osteoporosis in both men and postmenopausal women. Clinical trials with Blosozumab have shown the antibody to be well tolerated and effective in producing a bone anabolic effect. Blosozumab was developed by Eli Lilly and Company. (en)
dbo:casNumber	1132758-87-2
dbo:fdaUniiCode	83YOM0NEL5
dbo:kegg	D10094
dbo:wikiPageID	33052058 (xsd:integer)
dbo:wikiPageLength	2855 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1084694430 (xsd:integer)
dbo:wikiPageWikiLink	dbr:Eli_Lilly_and_Company dbc:Eli_Lilly_and_Company_brands dbr:SOST
dbp:atcPrefix	none (en)
dbp:c	6462 (xsd:integer)
dbp:casNumber	1132758 (xsd:integer)
dbp:chemspiderid	none (en)
dbp:h	9852 (xsd:integer)
dbp:kegg	D10094 (en)
dbp:mabType	mab (en)
dbp:n	1684 (xsd:integer)
dbp:o	2030 (xsd:integer)
dbp:s	46 (xsd:integer)
dbp:source	zu/o (en)
dbp:target	dbr:SOST
dbp:type	mab (en)
dbp:unii	83 (xsd:integer)
dbp:verifiedfields	changed (en)
dbp:verifiedrevid	457463532 (xsd:integer)
dbp:watchedfields	changed (en)
dbp:wikiPageUsesTemplate	dbt:Monoclonals_for_bone,_musculoskeletal,_circulatory,_and_neurologic_systems dbt:Drugbox dbt:Musculoskeletal-drug-stub dbt:Reflist dbt:Short_description dbt:Cascite dbt:Chemspidercite dbt:Drugbankcite dbt:Fdacite dbt:Keggcite dbt:Monoclonal-antibody-stub
dcterms:subject	dbc:Eli_Lilly_and_Company_brands
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:MonoclonalAntibody yago:WikicatMonoclonalAntibodies yago:Abstraction100002137 yago:Antibody115027189 yago:Chemical114806838 yago:Compound114818238 yago:Macromolecule114944888 yago:Material114580897 yago:Matter100020827 yago:Molecule114682133 yago:MonoclonalAntibody115029781 yago:OrganicCompound114727670 yago:Part113809207 yago:PhysicalEntity100001930 yago:Protein114728724 yago:Relation100031921 dbo:Drug yago:Substance100019613 yago:Thing100002452 yago:Unit109465459
rdfs:comment	بلوسوزوماب هو جسم مضاد وحيد النسيلة يدرب ليستخدم في علاج تخلخل العظم. طورته . (ar) Blosozumab binds SOST, a negative regulator of osteoblast activity. Blocking SOST activity can lead to increased bone density. Blosozaumab has been studied with regards to the treatment of osteoporosis in both men and postmenopausal women. Clinical trials with Blosozumab have shown the antibody to be well tolerated and effective in producing a bone anabolic effect. Blosozumab was developed by Eli Lilly and Company. (en)
rdfs:label	بلوسوزوماب (ar) Blosozumab (en)
owl:sameAs	freebase:Blosozumab yago-res:Blosozumab wikidata:Blosozumab dbpedia-ar:Blosozumab https://global.dbpedia.org/id/4Zrsc
prov:wasDerivedFrom	wikipedia-en:Blosozumab?oldid=1084694430&ns=0
foaf:isPrimaryTopicOf	wikipedia-en:Blosozumab
is dbo:wikiPageRedirects of	dbr:C6462H9852N1684O2030S46
is dbo:wikiPageWikiLink of	dbr:C6462H9852N1684O2030S46 dbr:Osteogenesis_imperfecta dbr:List_of_therapeutic_monoclonal_antibodies dbr:List_of_drugs:_Bi–Bo
is foaf:primaryTopic of	wikipedia-en:Blosozumab